Delisting Determination, The Nasdaq Stock Market, LLC,
April 28, 2020,  Sophiris Bio, Inc. The Nasdaq Stock Market LLC
(the Exchange) has determined to remove from listing the
common shares of  Sophiris Bio, Inc. (the Company), effective
at the opening of the trading session on May 8, 2020.
Based on review of information provided by the Company, Nasdaq
Staff determined that the Company no longer qualified for listing
on the Exchange pursuant to Listing Rule 5550(b)(2). The Company
was notified of the Staff determination on September 6, 2019.
The Company appealed the determination to a Hearing Panel on
September 12, 2019. On October 21, 2019, the Company granted
an exception to the Company. On December 3, 2019, Staff
notified the Company of an additional delist determination
for failure to comply with Listing Rule 5550(a)(2).
On March 10, 2020, upon review of the matter, the Panel
issued a decision denying the Company continued listing
and notified the Company that trading in the Company securities
would be suspended on March 12, 2020.
The Listing Council did not call the matter for review.
The Staff determination to delist the Company became final
on April 24, 2020.